Pancreatic Cancer - Obesity Reviews, Recent Papers, and Clinical Trials
To see all of the current 31 Reviews, go directly to PubMED.
Reviews from PubMed – November 11, 2023 – Obesity (in title) AND Cancer (in title) AND Pancreatic (in title) and Review
- Decoding the obesity-cancer connection: lessons from preclinical models of pancreatic adenocarcinoma August 30, 2023Obesity is a metabolic state of energy excess and a risk factor for over a dozen cancer types. Because of the rising worldwide prevalence of obesity, decoding the mechanisms by which obesity promotes tumor initiation and early progression is a societal imperative and could broadly impact human health. Here, we review results from preclinical models […]Christian F Ruiz
- Pancreatic Cancer and the Obesity Epidemic: A Narrative Review August 12, 2022Pancreatic cancer (PC) is one of the most frequent causes of death. It usually affects older individuals with incidence closely approaching mortality due to its early asymptomatic feature and highly metastatic nature. Multiple risk factors such as family history, smoking, and germline mutations are associated with PC development, with obesity being one of the controllable […]Devyani S Poman
- Obesity and Pancreatic Cancer: Recent Progress in Epidemiology, Mechanisms and Bariatric Surgery June 24, 2022More than 30% of people in the United States (US) are classified as obese, and over 50% are considered significantly overweight. Importantly, obesity is a risk factor not only for the development of metabolic syndrome but also for many cancers, including pancreatic ductal adenocarcinoma (PDAC). PDAC is the third leading cause of cancer-related death, and […]Shuhei Shinoda
- Obesity and Pancreatic Cancer: Insight into Mechanisms October 23, 2021The prevalence of obesity in adults and children has dramatically increased over the past decades. Obesity has been declared a chronic progressive disease and is a risk factor for a number of metabolic, inflammatory, and neoplastic diseases. There is clear epidemiologic and preclinical evidence that obesity is a risk factor for pancreatic cancer. Among various […]Guido Eibl
- Pancreatic Macrophages: Critical Players in Obesity-Promoted Pancreatic Cancer July 26, 2020Obesity is a known risk factor for the development of pancreatic cancer, one of the deadliest types of malignancies. In recent years it has become clear that the pancreatic microenvironment is critically involved and a contributing factor in accelerating pancreatic neoplasia. In this context obesity-associated chronic inflammation plays an important role. Among several immune cells, […]Yaroslav Teper
- The Impact of obesity and diabetes mellitus on pancreatic cancer: Molecular mechanisms and clinical perspectives May 28, 2020The incidence of obesity and type 2 diabetes (T2DM) in the Western world has increased dramatically during the recent decades. According to the American Cancer Society, pancreatic cancer (PC) is the fourth leading cause of cancer-related death in the United States. The relationship among obesity, T2DM and PC is complex. Due to increase in obesity, […]Bao Quoc Lam
- The intricate relationship between diabetes, obesity and pancreatic cancer November 11, 2019Pancreatic cancer is one of the leading determinants of global cancer mortality, and its incidence is predicted to increase, to become in 2030 the second most common cause of cancer-related death. Obesity and diabetes are recognized risk factors for the development of pancreatic cancer. In the last few decades an epidemic of diabetes and obesity […]Silvano Paternoster
- Obesity and pancreatic cancer: An update of epidemiological evidence and molecular mechanisms August 27, 2019Despite advances in therapy and achievements in translational research, pancreatic cancer (PC) remains an invariably fatal malignancy. Risk factors that affect the incidence of PC include diabetes, smoking, obesity, chronic pancreatitis, and diet. The growing worldwide obesity epidemic is associated with an increased risk of the most common cancers, including PC. Chronic inflammation, hormonal effects, […]Bin Zhou
- Reply letter to: "Response to: Sarcopenia and sarcopenic obesity are significantly associated with poorer overall survival in patients with pancreatic cancer: Systematic review and meta-analysis" March 8, 2019No abstractIoannis Mintziras
- Comments on: Sarcopenia and sarcopenic obesity are significantly associated with poorer overall survival in patients with pancreatic cancer: Systematic review and meta-analysis March 6, 2019No abstractSivesh K Kamarajah
- Pancreatic cancer and obesity: epidemiology, mechanism, and preventive strategies February 22, 2019The prevalence of obesity has seen a global increase in the past decades, escalating to one of the major epidemiological challenges today. Global economic growth has caused changes in dietary and physical activity patterns fueling obesity across age, gender, and income groups. The implications are many, as obesity has been associated with numerous serious health […]Prashanth Rawla
- Pancreatic cancer associated with obesity and diabetes: an alternative approach for its targeting December 21, 2018CONCLUSIONS: Metabolic diseases, such as obesity and T2DM, contribute PC development through altered metabolic pathways. Delineating key players in oncogenic development in pancreas due to metabolic disorder could be a beneficial strategy to combat cancers associated with metabolic diseases in particular, PC.Ramesh Pothuraju
- Pancreatic Cancer and Obesity: Molecular Mechanisms of Cell Transformation and Chemoresistance October 28, 2018Cancer and obesity are the two major epidemics of the 21st century. Pancreatic ductal adenocarcinoma (PDAC) is one of the leading causes of death, with a five-year overall survival rate of only 8%. Its incidence and mortality have increased in recent years, and this cancer type is expected to be among the top five leading […]Priscilla Cascetta
- Sarcopenia and sarcopenic obesity are significantly associated with poorer overall survival in patients with pancreatic cancer: Systematic review and meta-analysis September 30, 2018CONCLUSIONS: Sarcopenia and sarcopenic obesity are significantly associated with poorer overall survival in patients with PDAC.Ioannis Mintziras
- Obesity and Pancreatic Cancer: Overview of Epidemiology and Potential Prevention by Weight Loss January 19, 2018Currently, there are no effective preventive strategies for pancreatic cancer. Obesity has been increasingly recognized as a strong but modifiable risk factor of pancreatic cancer. In this article, we aim to review the literature regarding weight loss on prevention of pancreatic cancer. Epidemiological and laboratory studies have shown that obesity is associated with increased incidence […]Mu Xu
- KRAS, YAP, and obesity in pancreatic cancer: A signaling network with multiple loops October 29, 2017Pancreatic ductal adenocarcinoma (PDAC) continues to be a lethal disease with no efficacious treatment modalities. The incidence of PDAC is expected to increase, at least partially because of the obesity epidemic. Increased efforts to prevent or intercept this disease are clearly needed. Mutations in KRAS are initiating events in pancreatic carcinogenesis supported by genetically engineered […]Guido Eibl
- Diabetes Mellitus and Obesity as Risk Factors for Pancreatic Cancer September 19, 2017Pancreatic ductal adenocarcinoma (PDAC) is among the deadliest types of cancer. The worldwide estimates of its incidence and mortality in the general population are eight cases per 100,000 person-years and seven deaths per 100,000 person-years, and they are significantly higher in the United States than in the rest of the world. The incidence of this […]Guido Eibl
- Obesity and Pancreatic Cancer December 3, 2016Pancreatic cancer has few known risk factors, providing little in the way of prevention, and is the most rapidly fatal cancer with 7 % survival rate at 5 years. Obesity has surfaced as an important risk factor for pancreatic cancer as epidemiological studies with strong methodological designs have removed important biases and solidified the obesity […]Dominique S Michaud
- The Impact of Obesity on Gallstone Disease, Acute Pancreatitis, and Pancreatic Cancer November 14, 2016Obesity is a well-recognized risk factor for gallstone formation and increases the risk for gallstone-related complications. Pancreatic diseases are impacted adversely by obesity. Although weight loss surgery increases the risk of gallstone disease, evidence suggests that bariatric surgery mitigates the obesity-associated adverse prognostication in acute pancreatitis. Obesity is also a significant risk factor for pancreatic […]Zobeida Cruz-Monserrate
- Peroxisome proliferator activated receptors at the crossroad of obesity, diabetes, and pancreatic cancer March 4, 2016Pancreatic ductal adenocarcinoma (PDAC) is the fourth cause of cancer death with an overall survival of 5% at five years. The development of PDAC is characteristically associated to the accumulation of distinctive genetic mutations and is preceded by the exposure to several risk factors. Epidemiology has demonstrated that PDAC risk factors may be non-modifiable risks […]Simone Polvani
To see all of the 85 Papers, go directly to PubMed.
RECENT PAPERS from PubMed – November 11, 2023 – Obesity (in title) AND Cancer (in title) AND Pancreatic (in title)
- Decoding the obesity-cancer connection: lessons from preclinical models of pancreatic adenocarcinoma August 30, 2023Obesity is a metabolic state of energy excess and a risk factor for over a dozen cancer types. Because of the rising worldwide prevalence of obesity, decoding the mechanisms by which obesity promotes tumor initiation and early progression is a societal imperative and could broadly impact human health. Here, we review results from preclinical models […]Christian F Ruiz
- Pancreatic Cancer and the Obesity Epidemic: A Narrative Review August 12, 2022Pancreatic cancer (PC) is one of the most frequent causes of death. It usually affects older individuals with incidence closely approaching mortality due to its early asymptomatic feature and highly metastatic nature. Multiple risk factors such as family history, smoking, and germline mutations are associated with PC development, with obesity being one of the controllable […]Devyani S Poman
- Obesity and Pancreatic Cancer: Recent Progress in Epidemiology, Mechanisms and Bariatric Surgery June 24, 2022More than 30% of people in the United States (US) are classified as obese, and over 50% are considered significantly overweight. Importantly, obesity is a risk factor not only for the development of metabolic syndrome but also for many cancers, including pancreatic ductal adenocarcinoma (PDAC). PDAC is the third leading cause of cancer-related death, and […]Shuhei Shinoda
- Obesity and Pancreatic Cancer: Insight into Mechanisms October 23, 2021The prevalence of obesity in adults and children has dramatically increased over the past decades. Obesity has been declared a chronic progressive disease and is a risk factor for a number of metabolic, inflammatory, and neoplastic diseases. There is clear epidemiologic and preclinical evidence that obesity is a risk factor for pancreatic cancer. Among various […]Guido Eibl
- Pancreatic Macrophages: Critical Players in Obesity-Promoted Pancreatic Cancer July 26, 2020Obesity is a known risk factor for the development of pancreatic cancer, one of the deadliest types of malignancies. In recent years it has become clear that the pancreatic microenvironment is critically involved and a contributing factor in accelerating pancreatic neoplasia. In this context obesity-associated chronic inflammation plays an important role. Among several immune cells, […]Yaroslav Teper
- The Impact of obesity and diabetes mellitus on pancreatic cancer: Molecular mechanisms and clinical perspectives May 28, 2020The incidence of obesity and type 2 diabetes (T2DM) in the Western world has increased dramatically during the recent decades. According to the American Cancer Society, pancreatic cancer (PC) is the fourth leading cause of cancer-related death in the United States. The relationship among obesity, T2DM and PC is complex. Due to increase in obesity, […]Bao Quoc Lam
- The intricate relationship between diabetes, obesity and pancreatic cancer November 11, 2019Pancreatic cancer is one of the leading determinants of global cancer mortality, and its incidence is predicted to increase, to become in 2030 the second most common cause of cancer-related death. Obesity and diabetes are recognized risk factors for the development of pancreatic cancer. In the last few decades an epidemic of diabetes and obesity […]Silvano Paternoster
- Obesity and pancreatic cancer: An update of epidemiological evidence and molecular mechanisms August 27, 2019Despite advances in therapy and achievements in translational research, pancreatic cancer (PC) remains an invariably fatal malignancy. Risk factors that affect the incidence of PC include diabetes, smoking, obesity, chronic pancreatitis, and diet. The growing worldwide obesity epidemic is associated with an increased risk of the most common cancers, including PC. Chronic inflammation, hormonal effects, […]Bin Zhou
- Reply letter to: "Response to: Sarcopenia and sarcopenic obesity are significantly associated with poorer overall survival in patients with pancreatic cancer: Systematic review and meta-analysis" March 8, 2019No abstractIoannis Mintziras
- Comments on: Sarcopenia and sarcopenic obesity are significantly associated with poorer overall survival in patients with pancreatic cancer: Systematic review and meta-analysis March 6, 2019No abstractSivesh K Kamarajah
- Pancreatic cancer and obesity: epidemiology, mechanism, and preventive strategies February 22, 2019The prevalence of obesity has seen a global increase in the past decades, escalating to one of the major epidemiological challenges today. Global economic growth has caused changes in dietary and physical activity patterns fueling obesity across age, gender, and income groups. The implications are many, as obesity has been associated with numerous serious health […]Prashanth Rawla
- Pancreatic cancer associated with obesity and diabetes: an alternative approach for its targeting December 21, 2018CONCLUSIONS: Metabolic diseases, such as obesity and T2DM, contribute PC development through altered metabolic pathways. Delineating key players in oncogenic development in pancreas due to metabolic disorder could be a beneficial strategy to combat cancers associated with metabolic diseases in particular, PC.Ramesh Pothuraju
- Pancreatic Cancer and Obesity: Molecular Mechanisms of Cell Transformation and Chemoresistance October 28, 2018Cancer and obesity are the two major epidemics of the 21st century. Pancreatic ductal adenocarcinoma (PDAC) is one of the leading causes of death, with a five-year overall survival rate of only 8%. Its incidence and mortality have increased in recent years, and this cancer type is expected to be among the top five leading […]Priscilla Cascetta
- Sarcopenia and sarcopenic obesity are significantly associated with poorer overall survival in patients with pancreatic cancer: Systematic review and meta-analysis September 30, 2018CONCLUSIONS: Sarcopenia and sarcopenic obesity are significantly associated with poorer overall survival in patients with PDAC.Ioannis Mintziras
- Obesity and Pancreatic Cancer: Overview of Epidemiology and Potential Prevention by Weight Loss January 19, 2018Currently, there are no effective preventive strategies for pancreatic cancer. Obesity has been increasingly recognized as a strong but modifiable risk factor of pancreatic cancer. In this article, we aim to review the literature regarding weight loss on prevention of pancreatic cancer. Epidemiological and laboratory studies have shown that obesity is associated with increased incidence […]Mu Xu
- KRAS, YAP, and obesity in pancreatic cancer: A signaling network with multiple loops October 29, 2017Pancreatic ductal adenocarcinoma (PDAC) continues to be a lethal disease with no efficacious treatment modalities. The incidence of PDAC is expected to increase, at least partially because of the obesity epidemic. Increased efforts to prevent or intercept this disease are clearly needed. Mutations in KRAS are initiating events in pancreatic carcinogenesis supported by genetically engineered […]Guido Eibl
- Diabetes Mellitus and Obesity as Risk Factors for Pancreatic Cancer September 19, 2017Pancreatic ductal adenocarcinoma (PDAC) is among the deadliest types of cancer. The worldwide estimates of its incidence and mortality in the general population are eight cases per 100,000 person-years and seven deaths per 100,000 person-years, and they are significantly higher in the United States than in the rest of the world. The incidence of this […]Guido Eibl
- Obesity and Pancreatic Cancer December 3, 2016Pancreatic cancer has few known risk factors, providing little in the way of prevention, and is the most rapidly fatal cancer with 7 % survival rate at 5 years. Obesity has surfaced as an important risk factor for pancreatic cancer as epidemiological studies with strong methodological designs have removed important biases and solidified the obesity […]Dominique S Michaud
- The Impact of Obesity on Gallstone Disease, Acute Pancreatitis, and Pancreatic Cancer November 14, 2016Obesity is a well-recognized risk factor for gallstone formation and increases the risk for gallstone-related complications. Pancreatic diseases are impacted adversely by obesity. Although weight loss surgery increases the risk of gallstone disease, evidence suggests that bariatric surgery mitigates the obesity-associated adverse prognostication in acute pancreatitis. Obesity is also a significant risk factor for pancreatic […]Zobeida Cruz-Monserrate
- Peroxisome proliferator activated receptors at the crossroad of obesity, diabetes, and pancreatic cancer March 4, 2016Pancreatic ductal adenocarcinoma (PDAC) is the fourth cause of cancer death with an overall survival of 5% at five years. The development of PDAC is characteristically associated to the accumulation of distinctive genetic mutations and is preceded by the exposure to several risk factors. Epidemiology has demonstrated that PDAC risk factors may be non-modifiable risks […]Simone Polvani
Clinical Trials involving Pancreatic Cancer and Obesity
| NCT Number | Study Title | Study URL | Acronym | Study Status | Interventions | Sponsor | Collaborators | Enrollment | Study Type | Locations |
|---|---|---|---|---|---|---|---|---|---|---|
| NCT05687188 | Evaluating Obesity-Mediated Mechanisms of Pancreatic Carcinogenesis in Minority Populations | https://clinicaltrials.gov/study/NCT05687188 | ACTIVE_NOT_RECRUITING | OTHER: Blood Sample Collection|OTHER: Tissue Sample Collection|OTHER: Data Collection|OTHER: Medical Image Collection | H. Lee Moffitt Cancer Center and Research Institute | United States Department of Defense | 91 | OBSERVATIONAL | Moffitt Cancer Center, Tampa, Florida, 33612, United States|University of Mississippi Medical Center, Jackson, Mississippi, 39216, United States | |
| NCT03910387 | Telotristat Ethyl to Promote Weight Stability in Patients With Advanced Stage Pancreatic Cancer | https://clinicaltrials.gov/study/NCT03910387 | ACTIVE_NOT_RECRUITING | DRUG: Gemcitabine|DRUG: Nab-paclitaxel|DRUG: Telotristat Ethyl | Emory University | National Cancer Institute (NCI)|Lexicon Pharmaceuticals | 22 | INTERVENTIONAL | Emory University Hospital Midtown, Atlanta, Georgia, 30308, United States|Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, 30322, United States|Emory Saint Joseph's Hospital, Atlanta, Georgia, 30342, United States | |
| NCT03851133 | Florida Pancreas Collaborative Next Generation Biobank | https://clinicaltrials.gov/study/NCT03851133 | ACTIVE_NOT_RECRUITING | OTHER: Blood Sample Collection|OTHER: Tumor Sample collection|OTHER: Data Collection | H. Lee Moffitt Cancer Center and Research Institute | 500 | OBSERVATIONAL | Lee Memorial Hospital Regional Cancer Center, Fort Myers, Florida, 33905, United States|University of Florida - Gainesville, Gainesville, Florida, 32610-0109, United States|Palmetto General Hospital, Hialeah, Florida, 33016, United States|University of Florida - Jacksonville, Jacksonville, Florida, 32209, United States|Lakeland Regional Health, Lakeland, Florida, 33805, United States|Mount Sinai Medical Center, Miami Beach, Florida, 33140, United States|Sylvester Comprehensive Cancer Center & Jackson Memorial Hospital, Miami, Florida, 33136, United States|Advent Health - Orlando, Orlando, Florida, 32804, United States|University of Florida - Orlando, Orlando, Florida, 32806, United States|St Anthony's Baycare/Bay Surgical Specialists, Saint Petersburg, Florida, 33705, United States|Sarasota Memorial Hospital, Sarasota, Florida, 34239, United States|Tallahassee Memorial Healthcare, Tallahassee, Florida, 32308, United States|University of South Florida/Tampa General Hospital, Tampa, Florida, 33606, United States|H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, 33612, United States | ||
| NCT00344851 | Exenatide and Metformin Therapy in Overweight Women With PCOS | https://clinicaltrials.gov/study/NCT00344851 | COMPLETED | DRUG: metformin, exenatide or combined (metformin & exenatide ) | Metabolic Center of Louisiana Research Foundation | Amylin Pharmaceuticals, LLC. | 60 | INTERVENTIONAL | Facility: Metabolic Center of Louisiana Research Foundation, Baton Rouge, Louisiana, 70808, United States | |
| NCT05874726 | Biological Sample Repository for Gastrointestinal Disorders | https://clinicaltrials.gov/study/NCT05874726 | RECRUITING | DIAGNOSTIC_TEST: Blood Collection|DIAGNOSTIC_TEST: Urine Collection|DIAGNOSTIC_TEST: Tissue Sample Collection | Pichamol Jirapinyo, MD, MPH | Tufts University|Boston Children's Hospital|Mayo Clinic | 500 | OBSERVATIONAL | Brigham and Women's Hospital, Boston, Massachusetts, 02115, United States | |
| NCT02432950 | Pancreatic Nutritional Program for Weight Loss in Overweight/Obese Patients With Stage I-III Breast Cancer | https://clinicaltrials.gov/study/NCT02432950 | COMPLETED | DIETARY_SUPPLEMENT: Dietary Intervention|OTHER: Educational Intervention|OTHER: Laboratory Biomarker Analysis|OTHER: Quality-of-Life Assessment | City of Hope Medical Center | National Cancer Institute (NCI) | 21 | INTERVENTIONAL | City of Hope Medical Center, Duarte, California, 91010, United States | |
| NCT04068896 | Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy | https://clinicaltrials.gov/study/NCT04068896 | ACTIVE_NOT_RECRUITING | BIOLOGICAL: NGM120|BIOLOGICAL: NGM120|BIOLOGICAL: NGM120|BIOLOGICAL: NGM120|BIOLOGICAL: NGM120|BIOLOGICAL: NGM120|OTHER: Placebo | NGM Biopharmaceuticals, Inc | 75 | INTERVENTIONAL | NGM Clinical Study Site, Tucson, Arizona, 85719, United States|NGM Clinical Study Site, Los Angeles, California, 90048, United States|NGM Clinical Study Site, Los Angeles, California, 90084, United States|NGM Clinical Study Site, Sacramento, California, 98517, United States|NGM Clinical Study Site, San Diego, California, 92123, United States|NGM Clinical Study Site, Santa Monica, California, 90404, United States|NGM Clinical Study Site, Aurora, Colorado, 80045, United States|NGM Clinical Study Site, Washington, District of Columbia, 20007, United States|NGM Clinical Study Site, Miami, Florida, 33136, United States|NGM Clinical Study Site, Chicago, Illinois, 60611, United States|NGM Clinical Study Site, Baltimore, Maryland, 21201, United States|NGM Clinical Study Site, Omaha, Nebraska, 68130, United States|NGM Clinical Study Site, Charlotte, North Carolina, 28204, United States|NGM Clinical Study Site, Cincinnati, Ohio, 45219, United States|NGM Clinical Study Site, Philadelphia, Pennsylvania, 19111, United States|NGM Clinical Study Site, Charleston, South Carolina, 29425, United States|NGM Clinical Study Site, Myrtle Beach, South Carolina, 29572, United States|NGM Clinical Study Site, Nashville, Tennessee, 37203, United States|NGM Clinical Study Site, Dallas, Texas, 75390, United States|NGM Clinical Study Site, Houston, Texas, 77030, United States|NGM Clinical Study Site, Seattle, Washington, 98101, United States|NGM Clinical Study Site, Milwaukee, Wisconsin, 53226, United States | ||
| NCT04210128 | Glucose Monitoring to Predict and Treat High Glucose Levels After Steroid Treatment | https://clinicaltrials.gov/study/NCT04210128 | COMPLETED | Memorial Sloan Kettering Cancer Center | 3 | OBSERVATIONAL | Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States | |||
| NCT02431676 | Survivorship Promotion In Reducing IGF-1 Trial | https://clinicaltrials.gov/study/NCT02431676 | SPIRIT | COMPLETED | DRUG: Metformin|BEHAVIORAL: Coach Directed Behavioral Weight Loss|BEHAVIORAL: Self-control weight loss | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Maryland Cigarette Restitution Fund | 121 | INTERVENTIONAL | Johns Hopkins ProHealth, Baltimore, Maryland, 21207, United States |